Methods This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify and evaluate in vitro studies investigating the effects of glucagon-like peptide-1 receptor agonists and their analogues on human mesenchymal stem cell functions, including proliferation, differentiation, signaling, apoptosis, and tissue-specific applications
This timeline indicates that the first cases may reach juries by late 2026 or early 2027, though the pace could accelerate if settlement negotiations gain momentum after key pretrial rulings
Doseresponse effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Helps manage conditions like type 2 diabetes and high blood pressure
Suspected adverse reactions should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
Ensuring adequate calcium, vitamin D, and protein intake, along with weight-bearing exercise, helps preserve bone health during weight reduction